Allakos reports Phase II data of AK002 for refractory chronic urticaria

Allakos Inc. (NASDAQ:ALLK) said AK002 improved urticaria control test scores in six of 11 Xolair omalizumab-refractory chronic spontaneous urticaria patients in a Phase II trial...